Zentraxa
Bristol
About Zentraxa
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $636.0K
- Funding stage: Seed
- Last round: Seed (May 2025)
- Website: zentraxa.com
Industries & Categories
Biotechnology, Test and Measurement
Social Profiles
Canonical: https://fsome.com/organization/zentraxa-160156 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.